
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
About The Study: This economic evaluation estimates that expanded Medicare coverage for glucagon-like peptide-1 receptor agonists (GLP-1RAs) would increase access and reduce obesity-related comorbidities but impose substantial costs over 10 years. Even …